Dr. Mao ChunSheng _^(He/Him)

Chief Executive Officer

The expert in biochemistry and molecular biology. He has successively engaged in molecular biology and immunology research at the Chinese Academy of Military Medical Sciences and the University of Massachusetts. In 2001, he joined Novagen Biotech, Canada, as the chief scientist, engaged in the research and development of new protein drugs. The drug he invented is the biological peptide ‘novaferon’ which has a good therapeutic effect on viral infections and cancer. It has obtained patents in more than 50 countries including the United States, China, Canada, and Europe. It is included in the China National Medical Insurance Procurement Catalog.

The “Recombinant Human Interferon-Like Proteins” (Recombinant Human Interferon-Like Proteins) invented by Dr. Mao is the core technology of China’s first-class new drug “Le Fu Neng”. This immunotherapy-based new drug has been the first-class innovative drug approved by China’s national new drug in Shandong Province in the past 14 years. The drug is mainly used for the treatment of chronic hepatitis B. It has also a good preventive and therapeutic effect on the new COVID infection.

Dr. Long XiaoYun _^(He/Him)

Consultant

He graduated from Anhui Medical University with a major in clinical medicine in 2001, and then went to London Class Business School and Renmin University of China to obtain a master’s degree and a doctorate degree in finance, respectively. As a senior investment banker, he has successively worked in financial institutions such as Merrill Lynch Securities, China Investment Securities and China Securities Construction Investment Securities. The amount of financing exceeded billions of dollars. Dr. Long’s research field also includes intellectual property and its securitization. In recent years, he has created and invested in a number of high-tech companies, covering industries such as financial technology and online healthcare.

Dr. Rui Zhang _^(She/Her) 

Chief Scientist

Dr. Zhang holds a Master’s and Doctoral degree in Infectious Disease Epidemiology from The Third Medical University. With extensive experience in the field, she has actively engaged in clinical practice, scientific research, and teaching. Her research covers various topics, including HBV immunopathogenesis, chronicization and severe progression of hepatitis B, and treatment methods for rabies and other infectious diseases. As a senior scientist of Canada’s Novagen Company since 2003, she has contributed to the development of biologic antiviral and anticancer drugs, leading to three patents in the United States and Europe.
In her current role, Dr. Zhang is responsible for guiding the molecular breeding of enzyme selection and overseeing the associated laboratory work. Her expertise and guidance play a crucial role in this process, contributing to the development and advancement of research in the field.

Dr. Yu HuaZhong _^(He/Him)

Consultant

He graduated from Peking University and worked successively in California Institute of Technology and the National NRC Academy of Sciences in Canada. He is now a tenured professor in the Department of Molecular Biology and Biochemistry at Simon Fraser University in Canada. He has published many high-level academic papers, held  US/international patents, and successively won the Analytical Chemistry Innovation Award of the Canadian Chemical Society, the Visiting Professor Award of the Japanese Society for the Promotion of Science, the Electrochemical Society (Lash Miller Award, Tajima of the International Electrochemical Society) Awards and more.